Organogenesis reports record Q4 2025 revenue $225M; FY2026 guidance implies 25-38% decline

Organogenesis Holdings Inc.

2025-FY EPS reported $0.15 revenue$564,169,000

Q4 2025 net product revenue $225.1M (+78% YoY); Advanced Wound Care $217.2M (+83% YoY).
Q4 net income $43.7M ($0.25/sh) vs $7.7M ($0.04/sh) a year ago; Adj. EBITDA $84.2M.
FY2025 net product revenue $563.0M (+17% YoY); net income $37.0M vs $0.9M in FY2024.
FY2026 total net revenue guidance $350M - $420M, a 25% to 38% decline from FY2025; expects Q1 drop then sequential growth.
Cash and equivalents $94.3M with no outstanding debt as of Dec 31, 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.